Claims for Patent: 6,960,355

Summary for Patent: 6,960,355

Title:	Compounds and compositions for delivering active agents
Abstract:	Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
Inventor(s):	Leone-Bay; Andrea (Ridgefield, CT), Milstein; Sam J. (Larchmont, NY), Sarrubi; Donald J. (Bronxville, NY), Leipold; Harry (Elmsford, NY)
Assignee:	Emisphere Technologies, Inc. (Tarrytown, NY)
Application Number:	10/005,511
Patent Claims:	1. A pharmacological composition comprising: (A) at least one biologically-active agent; and (B) at least one carrier compound having the formula or a salt thereof, wherein Ar is a phenyl or naphthyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H; R.sup.7 is selected form the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkyl)phenyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl (C.sub.1 to C.sub.10 alkyl), phenyl (C.sub.1 to C.sub.10 alkenyl), naphthyl (C.sub.1 to C.sub.10 alkyl) and naphthyl (C.sub.1 to C.sub.10 alkenyl); R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof; R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; R.sup.8 is selected from the group consisting of hydrogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, hydroxy, and C.sub.1 to C.sub.4 alkoxy; and R.sup.8 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof; R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl, or C.sub.1 to C.sub.4 alkenyl; with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group. 2. The composition of claim 1 wherein Ar is a phenyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H. 3. The composition of claim 1, wherein Ar is a phenyl substituted with --Cl. 4. The composition of claim 1, wherein Ar is a phenyl substituted with --F. 5. The composition of claim 3, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkenyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 6. The composition of claim 3, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 7. The composition of claim 6, wherein R.sup.7 is not substituted or interrupted. 8. The composition of claim 7, wherein R.sup.8 is hydrogen. 9. The composition of claim 1, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 10. The composition of claim 9, wherein the biologically active agent is a peptide. 11. The composition of claim 9, wherein the biologically active agent is a mucopolysaccharide. 12. The composition according to claim 1, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof. 13. The composition according to claim 12, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial, an antigen or a combination thereof. 14. The composition according to claim 13, wherein said biologically-active agent comprises human growth hormone. 15. The composition according to claim 13, wherein said biologically-active agent comprises insulin. 16. The composition according to claim 13, wherein said biologically-active agent comprises heparin. 17. The composition according to claim 13, wherein said biologically-active agent comprises low molecular weight heparin. 18. The composition according to claim 13, wherein said biologically-active agent comprises calcitonin. 19. The composition according to claim 13, wherein said biologically-active agent comprises cromolyn sodium. 20. The composition according to claim 13, wherein said biologically-active agent comprises parathyroid hormone. 21. A dosage unit form comprising (A) a pharmacological composition according to claim 1; and (B) (i) an excipient, (ii) a diluent (iii) a disintegrant (iv) a lubricant, (v) a plasticizer, (vi) a colorant, (vii) a dosing vehicle, or (viii) any combination thereof. 22. The dosage unit form according to claim 21, comprising a tablet, a capsule, or a liquid. 23. The dosage unit form according to claim 21, wherein said dosing vehicle is selected form the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof. 24. A method for preparing a pharmacological composition, said method comprising mixing: (A) at least one biologically-active agent; (B) at least one carrier compound having the formula wherein Ar is a phenyl or naphthyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H; R.sup.7 is selected form the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkyl)phenyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl (C.sub.1 to C.sub.10 alkyl), phenyl (C.sub.1 to C.sub.10 alkenyl), naphthyl (C.sub.1 to C.sub.10 alkyl) and naphthyl (C.sub.1 to C.sub.10 alkenyl); R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof; R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; R.sup.8 is selected from the group consisting of hydrogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, hydroxy, and C.sub.1 to C.sub.4 alkoxy; and R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl, or C.sub.1 to C.sub.4 alkenyl; with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; and (C) optionally a dosing vehicle. 25. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 1. 26. A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 1. 27. The composition of claim 1, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl) and wherein R.sup.8 is hydrogen. 28. The composition of claim 1, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl and wherein R.sup.8 is hydrogen. 29. The composition of claim 1, wherein R.sup.7 is riot substituted or interrupted and wherein R.sup.8 is hydrogen. 30. The composition of claim 1, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl) and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 31. The composition of claim 1, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 32. The composition of claim 1, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 33. The composition of claim 1, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 34. The composition of claim 1, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 35. The composition of claim 1, wherein R.sup.7 is not substituted or interrupted. 36. The composition of claim 1, wherein R.sup.8 is hydrogen. 37. The composition of claim 1, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 38. The composition of claim 2, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl) and wherein R.sup.8 is hydrogen. 39. The composition of claim 2, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl and wherein R.sup.8 is hydrogen. 40. The composition of claim 2, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is hydrogen. 41. The composition of claim 2, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl) and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 42. The composition of claim 2, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 43. The composition of claim 2, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 44. The composition of claim 2, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 45. The composition of claim 2, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 46. The composition of claim 2, wherein R.sup.7 is not substituted or interrupted. 47. The composition of claim 2, wherein R.sup.8 is hydrogen. 48. The composition of claim 2, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 49. The composition of claim 2, wherein the biologically active agent is a peptide. 50. The composition of claim 2, wherein the biologically active agent is a mucopolysaccharide. 51. The composition of claim 3, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is hydrogen. 52. The composition of claim 3, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 53. The composition of claim 3, wherein R.sup.7 is not substituted or interrupted. 54. The composition of claim 3, wherein R.sup.8 is hydrogen. 55. The composition of claim 3, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 56. The composition of claim 3, wherein the biologically active agent is a peptide. 57. The composition of claim 3, wherein the biologically active agent is a mucopolysaccharide. 58. The composition of claim 4, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl) and wherein R.sup.8 is hydrogen. 59. The composition of claim 4, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl and wherein R.sup.8 is hydrogen. 60. The composition of claim 4, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is hydrogen. 61. The composition of claim 4, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl) and wherein R.sub.8 is C.sub.1 -C.sub.4 alkyl. 62. The composition of claim 4, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 63. The composition of claim 4, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 64. The composition of claim 4, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 65. The composition of claim 4, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 66. The composition of claim 4, wherein R.sup.7 is not substituted or interrupted. 67. The composition of claim 4, wherein R.sup.8 is hydrogen. 68. The composition of claim 4, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 69. The composition of claim 4, wherein the biologically active agent is a peptide. 70. The composition of claim 4, wherein the biologically active agent is a mucopolysaccharide. 71. The composition of claim 5, wherein R.sup.7 is not substituted or interrupted. 72. The composition of claim 5, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 73. The composition of claim 5, wherein R.sup.7 is not substituted or interrupted and wherein R.sup.8 is hydrogen. 74. The composition of claim 5, wherein R.sup.8 is hydrogen. 75. The composition of claim 5, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 76. The composition of claim 5, wherein the biologically active agent is a peptide. 77. The composition of claim 5, wherein the biologically active agent is a mucopolysaccharide. 78. The composition of claim 6, wherein R.sup.8 is hydrogen. 79. The composition of claim 6, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 80. The composition of claim 6, wherein the biologically active agent is a peptide. 81. The composition of claim 6, wherein the biologically active agent is a mucopolysaccharide. 82. The composition of claim 7, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 83. The composition of claim 7, wherein the biologically active agent is a peptide. 84. The composition of claim 7, wherein the biologically active agent is a mucopolysaccharide. 85. The composition of claim 8, wherein the biologically active agent is a peptide. 86. The composition of claim 8, wherein the biologically active agent is a mucopolysaccharide. 87. The composition according to claim 13, wherein said biologically-active agent comprises interferon. 88. The composition according to claim 13, wherein said biologically-active agent comprises erythropoietin. 89. The composition according to claim 13, wherein said biologically-active agent comprises an antigen. 90. The composition according to claim 13, wherein said biologically-active agent comprises an antimicrobial. 91. The dosage unit form according to claim 21, wherein Ar is a phenyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H. 92. The dosage unit form according to claim 21, wherein Ar is a phenyl substituted with --Cl. 93. The dosage unit form according to claim 21, wherein R.sup.8 is hydrogen. 94. The dosage unit form according to claim 21, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 95. The dosage unit form according to claim 21, wherein said biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 96. The dosage unit form according to claim 21, wherein said biologically active agent is a peptide. 97. The dosage unit form according to claim 21, wherein said biologically active agent is a mucopolysaccharide. 98. The dosage unit form according to claim 21, wherein said biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof. 99. The dosage unit form according to claim 21, wherein Ar is a phenyl substituted with --F. 100. The dosage unit form according to claim 21, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 101. The dosage unit form according to claim 21, wherein R.sup.7 is (C.sub.4 -C.sub.20 alkyl. 102. The dosage unit form according to claim 21, wherein R.sup.7 is not substituted or interrupted. 103. The dosage unit form according to claim 21, comprising a tablet. 104. The dosage unit form according to claim 21, comprising a capsule. 105. The method according to claim 24, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 106. The method according to claim 24, wherein the biologically active agent is a peptide. 107. The method according to claim 24, wherein the biologically active agent is a mucopolysaccharide. 108. The method according to claim 24, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof. 109. The method according to claim 24, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof. 110. The method according to claim 24, wherein said biologically-active agent comprises human growth hormone. 111. The method according to claim 24, wherein said biologically-active agent comprises insulin. 112. The method according to claim 24, wherein said biologically-active agent comprises heparin. 113. The method according to claim 24, wherein said biologically-active agent comprises low molecular weight heparin. 114. The method according to claim 24, wherein said biologically-active agent comprises calcitonin. 115. The method according to claim 24, wherein said biologically-active agent comprises cromolyn sodium. 116. The method according to claim 24, wherein said biologically-active agent comprises parathyroid hormone. 117. The method according to claim 24, wherein said biologically-active agent comprises interferon. 118. The method according to claim 24, wherein said biologically-active agent comprises erythropoietin. 119. The method according to claim 24, wherein said biologically-active agent comprises an antigen. 120. The method according to claim 24, wherein said biologically-active agent comprises an antimicrobial. 121. The method according to claim 24, wherein Ar is a phenyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H. 122. The method according to claim 24, wherein Ar is a phenyl substituted with --Cl. 123. The method according to claim 24, wherein Ar is a phenyl substituted with --F. 124. The method according to claim 24, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 125. The method according to claim 24, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 126. The method according to claim 24, wherein R.sup.7 is not substituted or interrupted. 127. The method according to claim 24, wherein R.sup.8 is hydrogen. 128. The method according to claim 24, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 129. The method according to claim 25, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 130. The method according to claim 25, wherein the biologically active agent is a peptide. 131. The method according to claim 25, wherein the biologically active agent is a mucopolysaccharide. 132. The method according to claim 25, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin in, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof. 133. The method according to claim 25, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof. 134. The method according to claim 25, wherein said biologically-active agent comprises human growth hormone. 135. The method according to claim 25, wherein said biologically-active agent comprises insulin. 136. The method according to claim 25, wherein said biologically-active agent comprises heparin. 137. The method according to claim 25, wherein said biologically-active agent comprises low molecular weight heparin. 138. The method according to claim 25, wherein said biologically-active agent comprises calcitonin. 139. The method according to claim 25, wherein said biologically-active agent comprises cromolyn sodium. 140. The method according to claim 25, wherein said biologically-active agent comprises parathyroid hormone. 141. The method according to claim 25, wherein said biologically-active agent comprises interferon. 142. The method according to claim 25, wherein said biologically-active agent comprises erythropoietin. 143. The method according to claim 25, wherein said biologically-active agent comprises an antigen. 144. The method according to claim 25, wherein said biologically-active agent comprises an antimicrobial. 145. The method according to claim 25, wherein Ar is a phenyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H. 146. The method according to claim 25, wherein Ar is a phenyl substituted with --Cl. 147. The method according to claim 25, wherein Ar is a phenyl substituted with --F. 148. The method according to claim 25, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 149. The method according to claim 25, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 150. The method according to claim 25, wherein R.sup.7 is not substituted or interrupted. 151. The method according to claim 25, wherein R.sup.8 is hydrogen. 152. The method according to claim 25, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 153. The method according to claim 26, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 154. The method according to claim 26, wherein the biologically active agent is a peptide. 155. The method according to claim 26, wherein the biologically active agent is a mucopolysaccharide. 156. The method according to claim 26, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof. 157. The method according to claim 26, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof. 158. The method according to claim 26, wherein said biologically-active agent comprises human growth hormone. 159. The method according to claim 26, wherein said biologically-active agent comprises insulin. 160. The method according to claim 26, wherein said biologically-active agent comprises heparin. 161. The method according to claim 26, wherein said biologically-active agent comprises low molecular weight heparin. 162. The method according to claim 26, wherein said biologically-active agent comprises calcitonin. 163. The method according to claim 26, wherein said biologically-active agent comprises cromolyn sodium. 164. The method according to claim 26, wherein said biologically-active agent comprises parathyroid hormone. 165. The method according to claim 26, wherein said biologically-active agent comprises interferon. 166. The method according to claim 26, wherein said biologically-active agent comprises erythropoietin. 167. The method according to claim 26, wherein said biologically-active agent comprises an antigen. 168. The method according to claim 26, wherein said biologically-active agent comprises an antimicrobial. 169. The method according to claim 26, wherein Ar is a phenyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H. 170. The method according to claim 26, wherein Ar is a phenyl substituted with --Cl. 171. The method according to claim 26, wherein Ar is a phenyl substituted with --F. 172. The method according to claim 26, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 173. The method according to claim 26, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 174. The method according to claim 26, wherein R.sup.7 is not substituted or interrupted. 175. The method according to claim 26, wherein R.sup.8 is hydrogen. 176. The method according to claim 26, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl. 177. A method for administering a biologically-active agent to a human in need of said agent, said method comprising administering orally to said human a composition as defined in claim 1. 178. The method according to claim 177, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. 179. The method according to claim 177, wherein the biologically active agent is a peptide. 180. The method according to claim 177, wherein the biologically active agent is a mucopolysaccharide. 181. The method according to claim 177, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof. 182. The method according to claim 177, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof. 183. The method according to claim 177, wherein said biologically-active agent comprises human growth hormone. 184. The method according to claim 177, wherein said biologically-active agent comprises insulin. 185. The method according to claim 177, wherein said biologically-active agent comprises heparin. 186. The method according to claim 177, wherein said biologically-active agent comprises low molecular weight heparin. 187. The method according to claim 177, wherein said biologically-active agent comprises calcitonin. 188. The method according to claim 177, wherein said biologically-active agent comprises cromolyn sodium. 189. The method according to claim 177, wherein said biologically-active agent comprises parathyroid hormone. 190. The method according to claim 177, wherein said biologically-active agent comprises interferon. 191. The method according to claim 177, wherein said biologically-active agent comprises erythropoietin. 192. The method according to claim 177, wherein said biologically-active agent comprises an antigen. 193. The method according to claim 177, wherein said biologically-active agent comprises an antimicrobial. 194. The method according to claim 177 wherein Ar is a phenyl substituted with at least one of C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.4 alkenyl, --F, --Cl, --OH, --SO.sub.2, --COOH or --SO.sub.3 H. 195. The method according to claim 177, wherein Ar is a phenyl substituted with --Cl. 196. The method according to claim 177, wherein Ar is a phenyl substituted with --F. 197. The method according to claim 177, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, (C.sub.1 -C.sub.10 alkyl)phenyl, and phenyl (C.sub.1 to C.sub.10 alkyl). 198. The method according to claim 177, wherein R.sup.7 is C.sub.4 -C.sub.20 alkyl. 199. The method according to claim 177, wherein R.sup.7 is not substituted or interrupted. 200. The method according to claim 177, wherein R.sup.8 is hydrogen. 201. The method according to claim 177, wherein R.sup.8 is C.sub.1 -C.sub.4 alkyl.

Details for Patent 6,960,355

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2016-03-29